Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales on June 5, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions on June 5, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The exercise price for the stock options was $146.03 per share, and 9,500 options were exercised.
• The sales of common stock occurred at weighted average prices ranging from $545.345 to $550.58.
• A total of 1,737 shares were sold at a weighted average price of $545.9885.
• An additional 2,808 shares were sold at a weighted average price of $546.8829.
• Further sales included 2,366 shares at $547.8478, 1,289 shares at $548.8134, and 1,202 shares at $549.7727.
• 98 shares were sold at a weighted average price of $550.531.
• These transactions were conducted under a 10b5-1 trading plan adopted on November 7, 2025.
• The plan is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt directly beneficially owns 40,513 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine insider transaction executed under a pre-arranged compliance plan rather than indicating new strategic developments or significant changes in the company's financial health.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures for insider stock sales.
• The exercise of stock options at a price of $146.03 and sale at significantly higher prices ($545.345 to $550.58) demonstrates substantial value realization for the executive.

Negatives

• A significant number of shares were disposed of by a key executive, which could be perceived negatively by the market if not adequately contextualized.
• The total number of shares sold across multiple transactions is substantial, representing a notable reduction in direct beneficial ownership by the CEO.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of a large block of options, introducing a time-bound element to future transactions.
• The plan's continuation is contingent on the exercise of 1,734,410 stock options, which expire on March 15, 2027, creating a potential future need for further transactions or forfeiture.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. These options expire on March 15, 2027.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO of a biotechnology company like United Therapeutics is a common practice to manage personal stock holdings in a compliant manner, especially given the often volatile nature of biotech stock prices.

Stakeholder Impact

• Shareholders: May interpret the CEO's stock sales as a signal, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: The CEO's stock transactions do not directly impact employee compensation or benefits but may influence morale depending on market perception.
• Management: The transactions reflect the executive's personal financial planning and adherence to corporate governance policies.

Next Steps

• Continue executing the 10b5-1 trading plan until its termination conditions are met.
• Monitor the exercise and expiration of remaining stock options.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine Rothblatt, Stock Options, Insider Trading, 10b5-1 Plan, Beneficial Ownership, Common Stock, Share Sale